Loading stock data…
GH
$89.52-1.65 (-1.81%)
Pre-Market$90.01+0.49 (+0.55%)· Last close May 5
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Guardant Health, Inc. in the Healthcare sector is trading at $89.52. The stock is currently 26% below its 52-week high of $120.74, remaining 6.6% above its 200-day moving average. Technical signals show neutral RSI of 59 and bullish MACD crossover, explaining why GH maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 59) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$89.52
Potential Upside
5%
Whystock Fair Value$94.00
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus21 analysts
Mean target$128.33+43.4%
Range$90.00 – $180.00
Fundamentals
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company offers Guardant360 CDx test, a liquid biopsy test for tumor mutation profiling; Guardant360 Liqu...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$11.75B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.65
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
416.71%
Volume
Today's trading volume
1.07M
Recent News
The Bull Case For Guardant Health (GH) Could Change Following New ESR1 Liquid Biopsy CDx Approval – Learn Why
On 4 May 2026, Guardant Health announced that the FDA approved its Guardant360 CDx liquid biopsy as a companion diagnostic for VEPPANU, enabling blood-based detection of ESR1 mutations in ER-positive/HER2-negative advanced or metastatic breast cancer after progression on endocrine therapy. This approval is Guardant360 CDx’s third ESR1 companion diagnostic indication and its 26th overall, underscoring the platform’s expanding clinical role across solid tumors and its broad coverage by...
Repligen (RGEN) Q1 Earnings and Revenues Beat Estimates
Repligen (RGEN) delivered earnings and revenue surprises of +24.97% and +1.53%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Does Guardant Health (GH) Have Long-Runway for Growth?
Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. Baron Health Care Fund (the Fund) declined 6.97% (Institutional Shares) in the quarter, compared to the 4.88% decline for the Russell 3000 Health Care Index (the Benchmark) and […]
Guardant Health (GH) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Guardant Health (GH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Guardant Health, Organon, Fortrea, QuidelOrtho, and Charles River Laboratories Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after a proposed 2027 federal budget revealed significant spending cuts for key health agencies.